- TM Capital served as exclusive financial advisor to Quantib B.V. (“Quantib”), a portfolio company of Holland Capital, in connection with its sale to RadNet, Inc. (NASDAQ: RDNT)
- Quantib is a leading radiology artificial intelligence (“AI”) and machine learning company focusing on clinical solutions for prostate cancer and neurodegeneration
- Quantib has multiple AI-based solutions with both CE mark and FDA 510(k) clearance, including Quantib Prostate for analysis of prostate MR images and Quantib Brain and Quantib ND to quantify brain abnormalities on MRI
- Holland Capital is a healthcare and technology-focused private equity firm headquartered in Amsterdam, The Netherlands
- RadNet is a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 350 owned and operated outpatient imaging centers
- The acquisition will further enable RadNet’s leadership in the development and deployment of AI to improve the care and health of patients
Client Testimonial
We selected TM Capital to advise on the sale of our business to a partner who could help us maximize the potential of our groundbreaking AI-based products and provide a vibrant workplace for our team. TM delivered this for us, and also achieved an outstanding result for our shareholders. The TM team was dedicated throughout this process and provided thoughtful advice and knowledge of our industry. They were successful in structuring an agreement that achieved the goals of all parties. We deeply appreciate their support.”- Arthur Post Uiterweer, CEO, Quantib BV
